Bottom line, nothing, except the stock price. I bought into edapy before the buyout of their prostatron divsion based on the discount to sales, and book value and the fact that the information pointed to the microwave treatment as an effective treatment for enlarged prostrate. (condition affects 14mil americans and reimbursement is approx 3200 i believe) If they got 10% of market and a license fee of 250/treatment (not unlike the visx for lasik) you can see the sales potential in the hundreds of millions of dollars.
My look at the balance sheets showed no debt. However, imo the market is in general inefficient and it will take time for this to be noticed. What would be good would be if edapy would buy back some of their shares or put the whole company on the block.
The way the deal looks now, ulgx could offer to buy the entire company at $2/share and sell off the other divisions after it was done and come out ahead of the current 8mil +stock (not that I would be happy at a $2 sellout anyway)